73results about How to "Effective immunity" patented technology

Normal tissue complications limit curative broadbeam radiotherapy to tumors including lung cancer. Radiation retinitis causing blindness limits quality of life and long term survival for patients with ocular melanoma. This invention pertains to alternative, normal tissue sparing 100 to 1,000 Gy microbeam radiations with least normal tissue complications and concomitant radio-immunotherapy by innate immune response of epidermis and dermis to low dose radiation with 50 kV X-rays. Total body skin radiation with former airport passenger screening machines with 50 kV X-ray is disclosed. Microbeams are generated without contaminating scatter and neutron radiations from collinear gamma ray and electron beam produced by inverse Compton interaction with high energy laser and electron beam and from proton and carbon ion beams in tissue equivalent cylindrical collimators. Extracorporeal immunotherapy and chemotherapy and apheresis of mutated subcellular particles released into circulation in response to cancer-therapies are by clinical continuous flow ultracentrifugation combined chromatography.

The invention discloses a preparation method and an application of a recombinant cold-adaptation attenuated influenza vaccine strain. The method comprises the following steps: importing an influenza virus hemagglutinin HA gene, an influenza virus neuraminidase NA gene as well as seven genes, namely PB2, PB1, PA, NP, M, NS1 and NS2, in an influenza virus to a host cell, and conducting cultivating, so that a recombinant virus is obtained. Tests prove that an attenuated influenza tetravalent vaccine, which is prepared by virtue of a 7+2 plasmid rescuing system, can achieve an excellent immune effect through nasal immunization; the influenza virus, which is recombined by the 7+2 plasmid rescuing system, has a property of being time-efficient; in accordance with the epidemic characteristics of influenza viruses in various years, effective targeted influenza vaccines can be prepared; and the preparation method is rapid, obvious in immunogenicity and immune protection effect, and good in safety; therefore, the problems on safety and stability of attenuated influenza vaccines which are prepared by virtue of a conventional method are solved, and a protection spectrum of the influenza vaccines is more comprehensive.

The present invention relates to a pharmaceutical combination of compositions for use in the treatment or prevention of a disease having cells bearing a target antigen as a vaccine and to a method for vaccination of a mammal, especially of a human for raising a cellular immune response directed against cells of the mammalian recipient, especially human recipient, which cells express a target antigen. The target antigen can e.g. be an autoantigen like a malignant antigen, i.e. a tumour-specific antigen. The pharmaceutical combination of compositions comprises a first composition and a second composition, wherein the second composition is for administration to recipient subsequent to the administration of the first composition, e.g. 2 to 10 days after the first composition. The pharmaceutical combination of compositions has the advantage of raising an effective antigen-specific T-cell response against cells bearing a target antigen that can be a malignant autoantigen, e.g. for raising an antigen-specific T-cell response against cells bearing a tumour-antigen. A further advantage is that the pharmaceutical combination of compositions can raise an antigen-specific T-cell response within a comparatively short time.

A system and method for effectively implementing an immunity mode in an electronic device includes a processor module for executing processing tasks for the electronic device. The processor module includes processor information, such as processor states and processor data, for executing the processing tasks. The electronic device also includes a protected memory for storing electronic information in an optimally secure manner. An immunity manager may then perform protection procedures to store at least a portion of the vulnerable processor information into the protected memory in response to an immunity mode trigger event such as the processor module entering an idle state.

The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug.

An oncolytic adenovirus vector and its potential application in cancer treatment and vaccination. The inventive vector (named Ad-TD-hIL12) is derived from the human adenovirus group C type 5, more particularly including deletion of three adenovirus genes E1A-CR2, E1B19K and E3gp-19K, and a fused cDNA sequence of p35 and p40 subunit of human IL12 placed under the control of the E3gp-19K promoter. The invention also includes a method to construct the triple gene-deleted vector (Ad-TD). The Ad-TD-hIL12 and Ad-TD-shIL12 (with a short p40 sequence of human IL 12) vectors can be used as targeted, genetically engineered agents for treatment of various solid tumors, via not only intratumoral injection, and also in intraperitoneal injection, without causing significant side effects, showing a superior antitumor efficacy and safety.

A microelectromechanical gyroscope includes a drive loop having a drive element and a drive loop circuitry. The drive loop circuitry includes a clock generating circuitry for generating from the quadrature-phase detection signal a test clock signal, an angular rate phase demodulation signal and a quadrature phase demodulation signal. A sense loop includes a sense element and sense loop circuitry for detecting angular rate and producing a force-feedback signal. A test signal generator receives a quadrature-phase detection signal to be used as a quadrature-phase carrier signal and the test clock signal A summing element sums a test signal with the force-feedback signal to form a sense feedback signal. A rate phase demodulator produces a rate signal by demodulating a sense signal received from the sense loop with the angular rate phase demodulation signal, and a quadrature-phase demodulator produces a quadrature-phase output signal.

The invention discloses a recombination attenuated salmonella typhimurium carrier vaccine of expression IBDV (Infectious Bursal Disease Virus) immunogenic gene, a preparation method and application thereof, in particular relates to oral attenuated salmonella typhimurium. The recombination attenuated salmonella typhimurium comprises a sequence disclosed by SEQ ID NO.1, and the recombination virus can express IBDV capsid protein VP2. The preparation method comprises the following steps of: inoculating the attenuated salmonella typhimurium in an LB substrate for culturing 18 hours; regulating bacterial concentration as 1010CFU / ml; and preparing the safe and effective oral attenuated salmonella typhimurium carrier vaccine for preventing IBD (Infectious Bursal Diseases).

The present invention relates to an attenuated strain of Ehrlichia canis and a vaccine comprising said attenuated strain for protection of mammals against ehrlichiosis. The invention further relates to methods of preventing ehrlichiosis and of attenuating the pathogenicity Ehrlichia canis.

Melanoma can be treated in a mammalian subject by administering to the subject an immunologically-effective amount of a xenogeneic melanoma-associated differentiation antigen. For example, genetic immunization with a plasmid containing a sequence encoding human gp75 has been shown to be effective in treatment of dogs with melanoma.

The invention discloses a recombinant baculovirus expressing Japanese Encephalitis Virus (JEV) immunogen genes and a preparation method and application thereof, particularly relates to a recombinant baculovirus comprising a sequence shown as SEQ ID NO.1 and displaying structural proteins E of the JEV on the surface. The preparation method comprises steps of utilizing the recombinant baculovirus to inoculate Sf9 insect cells, culturing for 48-72h, collecting infection cells, carrying out freeze thawing at 40DEG C below zero / 37DEG C, centrifuging, taking supernate to test virus PFU and adjusting the titer of the virus to 109PFU / ml to obtain a safe and effective gene engineered subunit vaccine for preventing swine JEV.

The present invention relates to a PRRSV and PCV-2 bivalent recombinant fowlpox live vector vaccine, which pertains to the field of biotechnology. The present invention aims at providing the PRRSV and PCV-2 bivalent recombinant fowlpox live vector vaccine which has ORF5, ORF3 genes to express the structural glycoprotein of the PRRSV and ORF2 gene to express PCV-2 nucleocapsid protein and can be used as the live vector vaccine for the prevention of PRRS and PCV-2 infection in our country. The present invention constructs the pMD18T-ORF2, pMD18T-ORF5 and pMD18T-ORF3 plasmids, the plasmids are inserted to the downstream of the compound promoter ATI-P7.5 multiplied by 20 of the fowlpox virus expression vector pUTAL, at the same time, the ORF2 gene of the PCV2 are inserted to the downstream of the linking promoter P7.5 multiplied by 16, and the present invention further constructs the recombinant fowlpox virus gene transfer plasmid pUTAL-ORF2-ORF5-ORF3 which contains the ORF3-ORF3 gene of the PRRSV and the ORF2 gene of the PCV2. The present invention can be used as the live vector vaccine for the prevention of PRRS-PCV2 in our country.

Disclosed are a method for preparing a ginseng polysaccharide for immune stimulation and a ginseng polysaccharide for immune stimulation prepared from the preparation method, the method comprising the steps of (1) adding ingredients; (2) performing an extraction; (3) performing a first filtration and cooling; (4) performing a second filtration; (5) performing a first concentration; (6) adding a concentrate to a fermentation alcohol; (7) separating into a supernatant and a precipitate; (8) collecting the precipitate; (9) dissolving in water; (10) performing a second concentration; (11) cold ageing; (12) performing a third concentration; (13) sterilizing; and (14) packaging into a product of the ginseng polysaccharide for immune stimulation in the form of a concentrate.

The invention relates to aquaculture animal disease control technologies, and particularly relates to a vibrio anguillarum divalent vaccine, a preparing method thereof and a using method of the vaccine. The vaccine is a bacterial suspension mixture of a vibrio anguillarum 01 serotype and a 02 serotype. The vibrio anguillarum 01 serotype and the 02 serotype are deposited in the general microbiology center of the China Committee for Culture Collection of Microorganisms on December 7, 2012 and respectively have an accession number namely CGMCC No.6942 and CGMCC No.6944. The divalent inactivated vaccine can protect susceptible fishes from being infected by pathogenic vibrio anguillarum. The divalent vaccine broadens the vaccine protection range, effectively irritates cultured fishes to generate specific immune response, and effectively provides immune protection for diseases. Preparation of the divalent vaccine is low in cost of used materials and safe to animals and the environment.

The present invention belongs to the field of biotechnology, and is especially one kind of recombinant live carrier vaccine co-expressing pig gyrate virus and foot and mouth disease virus. The present invention aims at providing two recombinant chicken pox viruses to co-express capsid protein ORF2 or its fusion protein ORF2-ORF1 of the China epidemic strain of type-II pig gyrate virus and the structural protein precursor P1 of the China epidemic strain NY00 of type-O foot and mouth disease virus, and for serving as the duplex live carrier gene engineering vaccine to prevent PCV2 and FMDV infection. The two recombinant chicken pox viruses can stimulate mouse to generate effective body fluid immunity and cell immunity, and are safe to experimental animals without any pathological phenomenon.

The invention provides a novel antigen combination of meningococcus and an application thereof. The antigen combination comprises fHbp V1 variant proteins, fHbp V2 variant proteins and NHBA proteins. The experiment shows that vaccines prepared from the antigen combination have an obvious synergistic effect and have high broad-spectrum meningococcus resistant capability.

The invention discloses an oral recombinant attenuated salmonella typhimurium live vector vaccine as well as a preparation method and application thereof, particularly relating to an oral attenuated salmonella typhimurium. The recombinant attenuated salmonella typhimurium has a sequence shown in SEQ ID NO.1, and can express PCV-2 capsid protein ORF2. The attenuated salmonella typhimurium is inoculated in an LB culture medium for culturing for 18 hours; and the concentration of the attenuated salmonella typhimurium is regulated to 1010CFU / ml to prepare a safe and effective oral attenuated salmonella typhimurium live vector vaccine used for preventing porcine circovirus diseases.

The invention discloses fusion protein sHA1-Fc and an application. The fusion protein sHA1-Fc of a highly pathogenic AIV (avian influenza virus) H5N1 and a chicken IgY Fc fragment is expressed by a Bacto-Bac expression system, has a molecular structure similar to IgY, and can penetrate a respiratory tract mucosal barrier of a chicken to enter the body under transfer of FcRy expressed in epithelial cells. A sequence of an sHA1-Fc fusion gene is represented as SEQ ID NO:1. The fusion protein is supplemented with a mucosal adjuvant and inoculates the chicken through nasal inhalation, thereby being capable of triggering an organism to generate effective mucosal immunity and triggering systemic immunity of the organism. Therefore, the organism is enabled to obtain anti-AIV local specific immunity and systemic immunity, the immune effect of the fusion protein is better than that of a commercial inactivated virus vaccine, and a new strategy is provided for development of a novel mucosal vaccine for poultry bird flu and other infectious diseases.

The invention discloses a recombinant attenuation salmonella typhimurium vector vaccine expressing a PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) immunogen gene and a preparation method and application thereof, and in particular relates to an oral attenuation salmonella typhimurium. The recombinant attenuation salmonella typhimurium has a sequence shown in SEQ ID NO.1, and can express PRRSV cyst membrane protein GP5. The attenuation salmonella typhimurium is inoculated in an LB (Lysogeny Broth) culture medium and cultured for 18h, and the bacterium concentration is regulated to be 1010CFU / ml, therefore, the safe and effective oral attenuation salmonella typhimurium live vector vaccine is prepared and used for preventing PRRS.

The invention discloses a freeze-drying slow-release protective agent used for preparing an adenovirus preparation and the adenovirus preparation and a preparation method thereof, which relate to thefield of an adenovirus preparation. The freeze-drying slow-release protective agent comprises a first solution containing sodium alginate and a second solution containing calcium chloride, the freeze-drying slow-release protective agent solves the problem of stability of an oral adenovirus preparation, has enteric characteristic, and can protect adenovirus from influence of gastric acid, and the preparation can keep stabilization under low-pH stomach environment, after entering into intestinal tract, the preparation is gradually disintegrated and releases adenovirus, and the adenovirus preparation is suitable for an oral administration mode, which overcomes inconvenience of an injection administration mode. The problem of easy deactivation of preservation of the adenovirus liquid preparation is solved, preservation time of the preparation is prolonged, the requirement of the adenovirus preparation on temperature during preservation and transport processes can be reduced, preparation stability is increased, and economic cost is reduced.

The present invention relates to a therapeutic peptide T specific immune therapy for use in the treatment of a cancer of an HLA-A2 (Human Leukocyte Antigen A2) positive patient, said treatment comprises a priming period consisting in two to three administrations of said therapeutic peptide T specific immune therapy, thereby inducing a memory T cell response.

The invention discloses a recombinant baculovirus expressing Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) immunogen genes and a preparation method and application thereof, particularly relates to a recombinant baculovirus comprising a sequence shown as SEQ ID NO.1 and displaying structural proteins GP3 of the PRRSV on the surface. The preparation method comprises steps of utilizing the recombinant baculovirus to inoculate insect cells, culturing for 48-72h, collecting infection cells, carrying out freeze thawing at 40DEG C below zero / 37DEG C, centrifuging, taking supernate to test virus PFU and adjusting the titer of the virus to 109PFU / ml to obtain a safe and effective gene engineered subunit vaccine for preventing PRRS.

The invention discloses a 2019-nCoV S-antigens for generating 2019-nCoV neutralizing antibodies and a method for preparing the 2019-nCoV S-antigens. According to the 2019-nCoV S-antigens and the method, the 2019-nCoV S-antigens comprise 2019-nCoV S-antigen trimers combined with a cell membrane based on a Flag tag. The 2019-nCoV S-antigens can generate high-titer neutralizing antibodies so as to more effectively immunize animals.

The invention belongs to the technical field of biological vaccine preparation, in particular to a porcine epidemic diarrhea recombinant baculovirus genetically engineered subunit vaccine and its preparation method and application. The present invention selects the S1 gene and M gene of the current new epidemic strain of PEDV as the reference sequence, uses the baculovirus expression system to express the S1 protein or part of the S1 protein and M protein, and prepares the obtained recombinant protein into a subunit vaccine for effective Control the occurrence of porcine epidemic diarrhea. The porcine epidemic diarrhea genetically engineered subunit vaccine prepared by the method of the present invention solves the defects of the current porcine epidemic diarrhea virus traditional vaccine, can be used to prevent and treat porcine epidemic diarrhea virus infection and related diseases caused by it, and can also It is also suitable for preparing the coating antigen of the ELISA kit for detecting porcine epidemic diarrhea virus antibody.

The invention relates to the fields of genetic engineering and veterinary biological pharmacy, and in particular discloses a subunit vaccine for porcine reproductive and respiratory syndrome as well as a preparation method and application of the subunit vaccine. The invention firstly provides a fusion protein, wherein an amino acid sequence of the fusion protein is as shown in SEQ ID No. 1; and then the invention provides the subunit vaccine for the porcine reproductive and respiratory syndrome, wherein the subunit vaccine comprises the fusion protein. The fusion protein in the subunit vaccinefor the porcine reproductive and respiratory syndrome is obtained by conducting fusion expression on an ORF5 full-length gene of a PRRSV NADC30-like strain, which is optimized by virtue of a codon, and a gene of pseudomonas aeruginosa, from which a Domain III structural Domain is removed, and by virtue of an insect baculovirus / insect cell expression system. The vaccine provided by the inventionis good in protective effect, capable of inducing effective humoral immunity and cellular immunity and is suitable for clinical prevention of the reproductive and respiratory syndrome.

A recombinant live-carrier vaccine for henpox is disclosed, which can express the structural protein HIV-1CNB and hIL-6. Three recombinant henpox virus strains vPUTAIL6-GAG, vPUTAIL6-GP and vPUTAIL6-GE can express the HIV-1CNB core protein gag, outer membrane protein gp120 or chimeric protein gap-gp120, and hIL-6. They can stimulate the organ to generate HIV-1 resistant specific homoral immune and cell immune. Its advantages are high safety and high genetic stability.

The invention provides a false virus granule vaccine with dengue fever virus recombination replicon as a core and method for preparation, wherein the vaccine can express antigens with high efficiency in the affected cells, the antigen can be extracted effectively with good immunity effect. The vaccine can be used for preventing and treating tumor and virosis.

The invention provides a novel meningococcus antigen composition and applications thereof. Specifically, the antigen composition comprises fHbp V1 mutant protein, fHbp V2 mutant protein, and NHBA protein. The experiment results show that a vaccine prepared from the antigen composition has a prominent synergistic effect and an excellent performance on resisting meningitis in a broad spectrum.